
    
      Primary Objective:

      To evaluate the percentage of complete molecular responses after two cycles of induction
      therapy composed of a single cycle of blinatumomab followed by chemotherapy. Molecular
      response id monitored by a patient-specific Ig/TCR rearrangements in an assay with the
      sensitivity of at least 10e-04.

      Outline:

      Run-in phase: dexamethasone 10 mg/m2 PO (day 1-7), cyclophosphamide IV 200 mg/m2 (day 3-5),
      vincristine 2 mg IV (day 6), daunorubicin 45 mg/m2 IV (day 6-7), G-CSF until recovery,
      methotrexate 15 mg IT.

      Day 11: Screening to the study. Induction I: blinatumomab 9 µg/day IV continuously (day
      12-19), dose step to 28 µg/day (day 19-40). Induction II: dexamethasone 10 mg/m2 PO (day
      50-54), vindesine 3 mg/m2 IV (day 50), methotrexate 1.5 g/m2 IV (day 50), etoposide 250 mg/m2
      IV (day 53-54), cytarabine 2x 2 g/m2 IV (day 54), G-CSF until recovery, methotrexate 15 mg +
      cytarabine 40 mg + dexamethasone 4 mg IT (day 60).

      Week 11: Primary endpoint assessment.

        -  Complete Remission (CR) and Complete Remission with incomplete blood count recovery(CRi)
           continue with Consolidation I;

        -  no CR/CRi: end of study, salvage regimen upon the investigator´s decision.

      Consolidation I (week 13): rituximab 375 mg/ m2 IV (day 0, if CD20+ at diagnosis),
      methotrexate 1.5 g/m2 IV (day 1, 15), PEG-asparaginase 2000 U/m2 IV (day 2, 16), 6-MP 60
      mg/m2 PO (day 1-7, 15-21), methotrexate 15 mg + cytarabine 40 mg + dexamethasone 4 mg IT (day
      1).

      Week 18 assessment:

        -  CR/CRi and MRD <10-4: continue the protocol;

        -  CR/CRi and MRD ≥10-4;

             -  and CR/CRi on day 40 or ≥50% reduction of bone marrow blasts on day 40: 1-2 cycles
                of blinatumomab followed by alloSCT;

             -  and no CR/CRi on day 40 and <50% reduction of bone marrow blasts on day 40: 1 cycle
                of high dose chemotherapy followed by alloSCT;

        -  relapse: end of study.

      Consolidation II (week 19): rituximab 375 mg/ m2 IV (day 0, if CD20+ at diagnosis),
      prednisone 60 mg/m2 PO (day 1-14), vindesine 3 mg/m2 IV (day 1, 7), adriamycine 50 mg/m2 IV
      (day 1, 7), cyclophosphamide 1000 mg/m2 IV (day 15), cytarabine 75 mg/m2 IV (day 17-20,
      24-27), thioguanine 60 mg/m2 PO (day 15-28), methotrexate 15 mg + cytarabine 40 mg +
      dexamethasone 4 mg IT (day 1), methotrexate 15 mg IT (day 17, 24). Consolidation III+VI (week
      27 and 43): rituximab 375 mg/ m2 IV (day 0, if CD20+ at diagnosis), methotrexate 1.5 g/m2 IV
      (day 1, 15), PEG-asparaginase 2000 U/m2 IV (day 2, 16), 6-MP 60 mg/m2 PO (day 1-7, 15-21).
      Consolidation IV (week 33): rituximab 375 mg/ m2 IV (day 0, if CD20+ at diagnosis),
      cytarabine 1000 mg/m2 IV (day 1, 3, 5), methotrexate 15 mg + cytarabine 40 mg + dexamethasone
      4 mg IT (day 8). Consolidation V (week 38): rituximab 375 mg/ m2 IV (day 0, if CD20+ at
      diagnosis), cyclophosphamide 1000 mg/m2 IV (day 1), cytarabine 500 mg/m2 IV (day 1),
      methotrexate 15 mg + cytarabine 40 mg + dexamethasone 4 mg IT (day 1).

      Maintenance (start at week 49, duration 12 months): 6-MP 60 mg/m2 PO daily, methotrexate 20
      mg/m2 weekly.

      (Doses of daunorubicin, methotrexate, cytarabine and PEG-asparaginase are reduced in patients
      >55 years.)
    
  